Conference call scheduled for October 1, 2007 at 1:00 p.m. (Eastern);
simultaneous webcast at http://www.adventrx.com
SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, today announced that it will host a
conference call and webcast on Monday, October 1st, 2007 to discuss results
from its Phase 2b clinical trial of ANX-510, or CoFactor, for the treatment
of metastatic colorectal cancer. Evan M. Levine, chief executive officer of
ADVENTRX, will host the conference call.
The conference call may be accessed by dialing (800) 665-0430 for
domestic callers and (913) 312-0402 for international callers. The webcast
will be available live via the Internet by accessing ADVENTRX's web site at
http://www.adventrx.com under "Investors". Replays of the webcast will be
available for 30 days, and a phone replay will be available through October
2, 2007 by dialing (888) 203-1112 and entering the passcode 8640821.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems, such as drug metabolism and
bioavailability, excessive toxicity and treatment resistance. More
information can be found on ADVENTRX's web site at http://www.adventrx.com.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com/
CONTACT:
Ioana C. Hone of ADVENTRX Pharmaceuticals,
+1-858-552-0866
|
